Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Current ART Clear all

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hiv
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Auburn, Alabama • San Francisco, California • Fort Lauderdale, Florida + 1 more

Conditions: HIV Infections
Interventions: Aldesleukin, HAART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Underage Drinking, Cannabis Use, Drinking, Teen, Drinking, College, College Drinking, Teen Drinking
Interventions: e-PBI; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 19 Years
Enrollment: 1,980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Atrial Fibrillation, Arrhythmia
Interventions: Left atrial ablation, Rate or Rhythm Control Therapy; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2,204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 76
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 66 more

Conditions: Mental Health Wellness 1
Interventions: Trauma-Sensitive Yoga + TAU, Chen Style Tai Chi + TAU, Treatment as Usual; Behavioral
Lead sponsor: University of Northern Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Cedar Falls, Iowa

Conditions: HIV Infections
Interventions: CARE+ Spanish computer counseling session, CARE+ Spanish brief computer risk assessment session; Other
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 1,049 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more

Conditions: HIV Infection
Interventions: dolutegravir, lamivudine, Continue current antiretroviral regimen; Drug
Lead sponsor: Babafemi Taiwo; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: HIV Infections, Human Immunodeficiency Virus
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more

Conditions: HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions: buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: HIV Infection
Interventions: Placebo, Maraviroc; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: San Francisco, California • Stanford, California • Chicago, Illinois + 1 more

Conditions: Schizophrenia Disorder, Schizoaffecitve Disorder, Aggression
Interventions: Mindfulness-Based Virtual Reality Intervention; Other
Lead sponsor: Manhattan Psychiatric Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: New York, New York • White Plains, New York

Conditions: HIV, HIV/AIDS
Interventions: Peg-IFN-α2b; Drug
Lead sponsor: The Wistar Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Taekwondo-based Fall Prevention Exercise Condition, Fall Prevention Education Control Condition
Interventions: Fall prevention exercise using Taekwondo, Live Strong and Safe Program on Fall Prevention; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 55 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: HIV Infection, HIV
Interventions: Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: HIV-1-infection
Interventions: 18F-Raltegravir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: 3BNC117-LS, 10-1074-LS; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years · Male only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 9 more

Conditions: HIV Infections
Interventions: Kaletra + Current Dual NRTI Backbone, Current Regimen; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Treatment regimen change; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 23
States / cities: Menlo Park, California • Stanford, California • Torrance, California + 15 more

Conditions: HIV Infections
Interventions: B/FTC/TAF, Current ART; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hiv
Interventions: Health education materials, Patient-provider decision tool; Behavioral
Lead sponsor: City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Brooklyn, New York • Congers, New York • Mamaroneck, New York + 3 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: ABC/DTG/3TC FDC, Ongoing cART regimen; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 87
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more

Search by objective public record fields.

Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People

Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

The Effects of Trauma-sensitive Yoga and Tai Chi on Mental Health

A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

A Virtual Reality Mindfulness Application for Aggression in Schizophrenia

Reducing Proviral HIV DNA With Interferon-a

Taekwondo Program for Preventing Falls in Older Adults

Baricitinib Curative Repression of HIV-1

Pharmacokinetics Distribution of Raltegravir by PET/MR

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

Metabolic Abnormalities - HIV Infected and Uninfected Males

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

(mo)BETTA Trial in Transwomen for Optimization of ART

Assessing Perceptions and Preferences Around Long-acting Injectables (APPLI)

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen